Enlivex's Allocetra™ Lands FDA RMAT Designation for Knee Osteoarthritis, Paving the Way for Expedited Review
ENLV sits 20% above its 52-week low of $6.416 on elevated volume (3.0× avg).
Summary
Enlivex has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for Allocetra™ in age-related knee osteoarthritis, supported by positive Phase I/IIa data. The designation enables expedited development and review, and the FDA has requested a Type B meeting to align on the ongoing Phase IIb trial.
Key Events · Product Development and Regulatory · ENLV
-
RMAT Designation Granted
Based on Phase I/IIa data showing significant improvements in pain and function, the FDA granted RMAT designation to Allocetra™ for age-related symptomatic knee osteoarthritis in patients 64 and older.
-
Expedited Regulatory Pathway
RMAT status brings intensive FDA engagement, potential eligibility for accelerated approval and priority review, and a Type B meeting—requested by the FDA—to discuss the development program.
-
Phase IIb Trial Underway
A randomized, controlled Phase IIb trial is enrolling 182 patients aged 64 and older across the U.S. and EU; top-line data are expected by the end of Q2 2027.
-
Large Unmet Medical Need
Osteoarthritis affects over 32 million Americans, a number projected to reach 78 million by 2040, with limited disease-modifying treatments currently available.
Analysis · ENLV · Life Sciences
Securing RMAT designation for Allocetra™ in age-related knee osteoarthritis marks a pivotal regulatory win. It not only validates the Phase I/IIa data but also unlocks a faster development trajectory, including the possibility of accelerated approval. With over 32 million Americans suffering from OA, the move addresses a vast unmet need and bolsters the clinical pipeline story alongside the company's digital asset treasury. The FDA's request for a Type B meeting signals active engagement, which could speed the Phase IIb program toward a pivotal trial.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENLV was trading at $7.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $115.5M. The 52-week trading range was $6.42 to $31.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.